A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia

Virgilio Gerald H. Evidente, Hubert H. Fernandez, Mark S. Ledoux, Allison Brashear, Susanne Grafe, Angelika Hanschmann, Cynthia L. Comella

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

IncobotulinumtoxinA (Xeomin®, NT 201), a preparation without accessory (complexing) proteins, has shown comparable efficacy and safety to onabotulinumtoxinA in treating cervical dystonia (CD). This study evaluated the efficacy and safety of repeated incobotulinumtoxinA injections in subjects with CD. Following a ≤20-week placebo-controlled, randomized, double-blind, single-dose main period, subjects could enter a ≤68-week prospective, randomized, double-blind, repeated-dose, flexible-interval (minimum 6 weeks) extension period with 240 U or 120 U of incobotulinumtoxinA (≤5 injections). Outcome measures included the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) and adverse events (AEs). Of 219 subjects completing the main period, 214 were randomized in the extension period to receive incobotulinumtoxinA 240 U (n = 111) or 120 U (n = 103); 169 subjects completed the extension period, with 90 receiving five injection sessions. Both doses of incobotulinumtoxinA provided statistically significant and clinically relevant improvements in mean TWSTRS-Total, -Severity, -Disability, and -Pain scores, from each injection session to respective 4-week follow-up visits. The most frequently reported AE was dysphagia (240 U: 23.4 %; 120 U: 12.6 %), which did not result in any study withdrawals. There was no impact of injection interval on the incidence of AEs (post hoc analysis). A major limitation of this study was the fixed dose design requested by regulatory authorities, which does not reflect clinical practice. However, repeated incobotulinumtoxinA injections (240 or 120 U; flexible intervals) provided sustained efficacy and were well tolerated, with no unexpected safety risks following repeated injections. The incidence of AEs was similar in subjects requiring repeated injections at shorter intervals (≤12 weeks) compared with those treated using longer intervals (>12 weeks).

Original languageEnglish (US)
Pages (from-to)1699-1707
Number of pages9
JournalJournal of Neural Transmission
Volume120
Issue number12
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

    Fingerprint

Keywords

  • Botulinum toxin
  • Dystonia
  • IncobotulinumtoxinA
  • NT 201
  • Xeomin

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Evidente, V. G. H., Fernandez, H. H., Ledoux, M. S., Brashear, A., Grafe, S., Hanschmann, A., & Comella, C. L. (2013). A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia. Journal of Neural Transmission, 120(12), 1699-1707. https://doi.org/10.1007/s00702-013-1048-3